Integrative Analysis of Large-cell Lung Cancer

Shanghai 10th People's Hospital1,000 enrolled

Overview

Integrative analysis of LCLC

The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Lung Cancer

Interventions

Normal lung tissueOTHER

The investigators will extract total protein, DNA and RNA from LCLC patients.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≤ 75 years with histologically proven LCLC * No severe major organ dysfunction * World Health Organization (WHO) performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy

Locations (3)

Ganzhou City People's Hospital

Ganzhou, Jiangxi, China

RECRUITING

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

5 years overall survival

Time frame: 5 years

Secondary Outcomes

5 years disease-free survival

Time frame: 5 years

Central Contacts

Da Fu, PhD

CONTACT

00-86-21-66301604 fu800da900@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.